JP2016533749A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533749A5 JP2016533749A5 JP2016537333A JP2016537333A JP2016533749A5 JP 2016533749 A5 JP2016533749 A5 JP 2016533749A5 JP 2016537333 A JP2016537333 A JP 2016537333A JP 2016537333 A JP2016537333 A JP 2016537333A JP 2016533749 A5 JP2016533749 A5 JP 2016533749A5
- Authority
- JP
- Japan
- Prior art keywords
- newcastle disease
- disease virus
- attenuated newcastle
- virus
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361873039P | 2013-09-03 | 2013-09-03 | |
| US61/873,039 | 2013-09-03 | ||
| PCT/EP2014/068619 WO2015032755A1 (en) | 2013-09-03 | 2014-09-02 | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129161A Division JP6862500B2 (ja) | 2013-09-03 | 2019-07-11 | 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533749A JP2016533749A (ja) | 2016-11-04 |
| JP2016533749A5 true JP2016533749A5 (enExample) | 2017-10-12 |
| JP6557234B2 JP6557234B2 (ja) | 2019-08-07 |
Family
ID=51492938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537333A Expired - Fee Related JP6557234B2 (ja) | 2013-09-03 | 2014-09-02 | 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法 |
| JP2019129161A Expired - Fee Related JP6862500B2 (ja) | 2013-09-03 | 2019-07-11 | 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129161A Expired - Fee Related JP6862500B2 (ja) | 2013-09-03 | 2019-07-11 | 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10519426B2 (enExample) |
| EP (3) | EP4101457A1 (enExample) |
| JP (2) | JP6557234B2 (enExample) |
| KR (2) | KR102310692B1 (enExample) |
| CN (2) | CN111944767A (enExample) |
| AU (2) | AU2014317215C1 (enExample) |
| CA (1) | CA2922071C (enExample) |
| CY (2) | CY1121993T1 (enExample) |
| DK (2) | DK3508209T3 (enExample) |
| EA (2) | EA202191926A3 (enExample) |
| ES (2) | ES2914577T3 (enExample) |
| HK (1) | HK1231393A1 (enExample) |
| HR (2) | HRP20190250T1 (enExample) |
| HU (1) | HUE042382T2 (enExample) |
| LT (2) | LT3508209T (enExample) |
| ME (1) | ME03345B (enExample) |
| MX (2) | MX367768B (enExample) |
| PL (2) | PL3508209T3 (enExample) |
| PT (2) | PT3041490T (enExample) |
| RS (2) | RS58332B1 (enExample) |
| SI (2) | SI3041490T1 (enExample) |
| SM (2) | SMT201900094T1 (enExample) |
| TR (1) | TR201902073T4 (enExample) |
| TW (1) | TWI653334B (enExample) |
| WO (1) | WO2015032755A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008007056A (es) | 2005-12-02 | 2008-11-12 | Sinai School Medicine | Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos. |
| WO2010091262A1 (en) | 2009-02-05 | 2010-08-12 | Mount Sinai School Of Medicine Of New York University | Chimeric newcastle disease viruses and uses thereof |
| KR102222157B1 (ko) | 2013-03-14 | 2021-03-03 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 뉴캐슬병 바이러스 및 이의 용도 |
| KR102310692B1 (ko) * | 2013-09-03 | 2021-10-12 | 메디뮨 리미티드 | 약독화된 뉴캐슬병 바이러스를 특징으로 하는 조성물 및 신생물을 치료하기 위한 사용 방법 |
| WO2015127501A1 (en) | 2014-02-27 | 2015-09-03 | Viralytics Limited | Combination method for treatment of cancer |
| EP3288595B1 (en) * | 2015-04-28 | 2020-12-30 | The University Of Georgia Research Foundation, Inc. | Piv5-based amplifying virus-like particles |
| WO2017118866A1 (en) | 2016-01-08 | 2017-07-13 | Replimune Limited | Engineered virus |
| EP3246410A1 (en) | 2016-05-19 | 2017-11-22 | Klinikum rechts der Isar der Technischen Universität München | Vsv/ndv hybrid viruses for oncolytic therapy of cancer |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| KR101964610B1 (ko) * | 2017-03-13 | 2019-04-03 | 대한민국 | 신규한 종양용해성 바이러스 및 이의 용도 |
| JOP20190256A1 (ar) * | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| CN107254450A (zh) * | 2017-07-20 | 2017-10-17 | 扬州大学 | 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法 |
| CN108486279A (zh) * | 2017-09-21 | 2018-09-04 | 山东省农业科学院家禽研究所 | 一种基于荧光定量pcr技术检测鸽新城疫病毒的方法 |
| EP3552608A1 (en) * | 2018-04-09 | 2019-10-16 | Rapo Yerape B.H. Ltd | Increased activity of oncoloytic newcastle disease virus |
| JP2021530501A (ja) * | 2018-07-13 | 2021-11-11 | アイカーン スクール オブ メディシン アット マウント サイナイ | 癌の治療のためのａｐｍｖ及びその使用 |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| CN110859968A (zh) * | 2019-11-21 | 2020-03-06 | 四川安可康生物医药有限公司 | 激活对肿瘤的系统免疫反应的基因生物药物 |
| EP4121453A2 (en) * | 2020-03-20 | 2023-01-25 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2021229270A1 (es) | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
| CN115197949A (zh) * | 2021-04-13 | 2022-10-18 | 江苏康缘瑞翱生物医药科技有限公司 | 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途 |
| US20220396809A1 (en) * | 2021-06-03 | 2022-12-15 | University Of Guelph | Engineered newcastle disease virus vector and uses thereof |
| KR20250144435A (ko) * | 2023-02-06 | 2025-10-10 | 사이안백 엘엘씨 | 변형된 piv5 백신 벡터: 제조 및 사용 방법 |
| KR20250083186A (ko) * | 2023-11-29 | 2025-06-09 | 주식회사 카브 | 재조합 뉴캣슬병 바이러스 벡터를 포함하는 암 치료용 약제학적 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7724558B1 (en) * | 1999-03-19 | 2010-05-25 | Nec Corporation | Magnetic signal transmission line |
| AU7607900A (en) * | 1999-09-22 | 2001-04-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| KR100801180B1 (ko) * | 2006-09-26 | 2008-02-05 | 주식회사 고려비엔피 | 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신 |
| EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| US20090208495A1 (en) * | 2008-02-14 | 2009-08-20 | Bayer Schering Pharma Ag | Anti-tumor effective paramyxovirus |
| WO2010091262A1 (en) * | 2009-02-05 | 2010-08-12 | Mount Sinai School Of Medicine Of New York University | Chimeric newcastle disease viruses and uses thereof |
| KR102222157B1 (ko) * | 2013-03-14 | 2021-03-03 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 뉴캐슬병 바이러스 및 이의 용도 |
| KR102310692B1 (ko) * | 2013-09-03 | 2021-10-12 | 메디뮨 리미티드 | 약독화된 뉴캐슬병 바이러스를 특징으로 하는 조성물 및 신생물을 치료하기 위한 사용 방법 |
| CN109099045A (zh) * | 2018-10-30 | 2018-12-28 | 浙江斯泰新材料科技股份有限公司 | 防松锁固型螺钉 |
-
2014
- 2014-09-02 KR KR1020217012332A patent/KR102310692B1/ko active Active
- 2014-09-02 HR HRP20190250TT patent/HRP20190250T1/hr unknown
- 2014-09-02 EP EP22160157.8A patent/EP4101457A1/en not_active Withdrawn
- 2014-09-02 ES ES18188565T patent/ES2914577T3/es active Active
- 2014-09-02 AU AU2014317215A patent/AU2014317215C1/en not_active Ceased
- 2014-09-02 ME MEP-2019-40A patent/ME03345B/me unknown
- 2014-09-02 HK HK17105137.4A patent/HK1231393A1/zh unknown
- 2014-09-02 SM SM20190094T patent/SMT201900094T1/it unknown
- 2014-09-02 WO PCT/EP2014/068619 patent/WO2015032755A1/en not_active Ceased
- 2014-09-02 HR HRP20220653TT patent/HRP20220653T1/hr unknown
- 2014-09-02 LT LTEP18188565.8T patent/LT3508209T/lt unknown
- 2014-09-02 EA EA202191926A patent/EA202191926A3/ru unknown
- 2014-09-02 SI SI201431082T patent/SI3041490T1/sl unknown
- 2014-09-02 MX MX2016002771A patent/MX367768B/es active IP Right Grant
- 2014-09-02 PT PT14761317T patent/PT3041490T/pt unknown
- 2014-09-02 EP EP14761317.8A patent/EP3041490B1/en active Active
- 2014-09-02 DK DK18188565.8T patent/DK3508209T3/da active
- 2014-09-02 RS RS20190176A patent/RS58332B1/sr unknown
- 2014-09-02 PT PT181885658T patent/PT3508209T/pt unknown
- 2014-09-02 CN CN202010064863.0A patent/CN111944767A/zh active Pending
- 2014-09-02 RS RS20220481A patent/RS63291B1/sr unknown
- 2014-09-02 ES ES14761317T patent/ES2708755T3/es active Active
- 2014-09-02 LT LTEP14761317.8T patent/LT3041490T/lt unknown
- 2014-09-02 SM SM20220214T patent/SMT202200214T1/it unknown
- 2014-09-02 CA CA2922071A patent/CA2922071C/en active Active
- 2014-09-02 PL PL18188565T patent/PL3508209T3/pl unknown
- 2014-09-02 DK DK14761317.8T patent/DK3041490T3/en active
- 2014-09-02 EP EP18188565.8A patent/EP3508209B1/en active Active
- 2014-09-02 PL PL14761317T patent/PL3041490T3/pl unknown
- 2014-09-02 CN CN201480048630.4A patent/CN106163532B/zh active Active
- 2014-09-02 TR TR2019/02073T patent/TR201902073T4/tr unknown
- 2014-09-02 KR KR1020167008307A patent/KR102285894B1/ko not_active Expired - Fee Related
- 2014-09-02 EA EA201690425A patent/EA039404B1/ru unknown
- 2014-09-02 JP JP2016537333A patent/JP6557234B2/ja not_active Expired - Fee Related
- 2014-09-02 SI SI201431957T patent/SI3508209T1/sl unknown
- 2014-09-02 HU HUE14761317A patent/HUE042382T2/hu unknown
- 2014-09-02 US US14/916,102 patent/US10519426B2/en active Active
- 2014-09-03 TW TW103130466A patent/TWI653334B/zh active
-
2016
- 2016-03-02 MX MX2019010364A patent/MX2019010364A/es unknown
-
2019
- 2019-02-08 CY CY20191100170T patent/CY1121993T1/el unknown
- 2019-06-24 AU AU2019204419A patent/AU2019204419B2/en not_active Ceased
- 2019-07-11 JP JP2019129161A patent/JP6862500B2/ja not_active Expired - Fee Related
- 2019-11-14 US US16/684,241 patent/US11471499B2/en active Active
-
2022
- 2022-05-25 CY CY20221100362T patent/CY1126790T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019193662A5 (enExample) | ||
| Zamarin et al. | Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions | |
| Janke et al. | Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy | |
| US11471499B2 (en) | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia | |
| Sánchez et al. | Oncolytic viruses for canine cancer treatment | |
| JP5296983B2 (ja) | Ｒｎａウイルスが導入された樹状細胞を含む抗癌剤 | |
| Collins et al. | Viral vectors in cancer immunotherapy: which vector for which strategy? | |
| BR112019020001A2 (pt) | linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais | |
| HRP20231025T1 (hr) | Onkolitički virus vakcinije | |
| JP2016531927A5 (enExample) | ||
| JP2014207903A5 (enExample) | ||
| WO2015193359A3 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
| JP2016503029A5 (enExample) | ||
| CN118436692A (zh) | 表达il12的溶瘤弹状病毒 | |
| JP2019508403A5 (enExample) | ||
| JP2016513115A5 (enExample) | ||
| Zhao et al. | Newcastle disease virus: a promising agent for tumour immunotherapy | |
| JP2019533015A5 (enExample) | ||
| JP2021530501A5 (enExample) | ||
| JP2015506179A5 (enExample) | ||
| JP2017522326A5 (enExample) | ||
| JP2018522880A5 (enExample) | ||
| Sokke Umeshappa et al. | CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination | |
| Lorence et al. | Replication-competent, oncolytic Newcastle disease virus for cancer therapy | |
| JP2025188115A (ja) | 新規遺伝子組換えワクシニアウイルス及びその利用 |